Skip to main content
. 2016 Mar 31;14:83. doi: 10.1186/s12967-016-0836-6

Table 2.

Adverse events

Patients 1 mg/kg/day 2 mg/kg/day Alternating All n = 24
Cohort 1/Schedule A n = 10 Cohort 2 n = 8 Schedule B n = 6
Completed 1st cycle 7/10 (70 %) 5/8 (63 %) 5/6 (83 %) 17/24 (71 %)
Toxicities grade (%) 2 3 4 2 3 4 2 3 4
Rash 1 4 2 29.2
Diarrhea 3 1 1 20.8
Anorexia 5 2 4 4 62.5
Weight loss 1 1 2 16.7
Anxiety 1 4.2
Nausia 3 1 16.7
Vomiting 4 16.7
Fatigue 4 4 5 1 2 2 75.0
Muscle weakness 1 1 6 1 1 41.7
Myalgia 2 3 1 1 29.2
Rhabdomyolysis 1 4.2a

aStudy related death